Provided by Tiger Fintech (Singapore) Pte. Ltd.

CITIUS ONCOLOGY INC

0.5711
-0.0169-2.87%
Post-market: 0.5681-0.0030-0.53%16:32 EDT
Volume:78.54K
Turnover:46.39K
Market Cap:40.86M
PE:-1.71
High:0.6060
Open:0.5800
Low:0.5710
Close:0.5880
Loading ...

Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate

Benzinga
·
15 Feb

Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
15 Feb

Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir

TIPRANKS
·
06 Feb

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services

THOMSON REUTERS
·
06 Feb

Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025

THOMSON REUTERS
·
06 Feb

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

PR Newswire
·
06 Feb

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

TIPRANKS
·
07 Jan

Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025

THOMSON REUTERS
·
07 Jan

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

PR Newswire
·
07 Jan

Citius Oncology to explore strategic alternatives

TipRanks
·
07 Jan

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
07 Jan

Citius Oncology Retains Jeffries to Consider Strategic Alternatives

MT Newswires Live
·
06 Jan

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

THOMSON REUTERS
·
06 Jan

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

PR Newswire
·
06 Jan

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

TIPRANKS
·
30 Dec 2024

Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate

Benzinga
·
30 Dec 2024